Search

Search Constraints

You searched for: Author/Creator Kindler, Hedy L

Search Results

1. A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma. Issue 1 (27th June 2013)

2. Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. Issue 4 (April 2022)

3. Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. Issue 6 (22nd June 2022)

4. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Issue 10 (October 2020)

5. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. Issue 6 (June 2021)

6. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. Issue 2 (19th February 2021)

7. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Issue 9 (September 2017)

8. Utilisation of a thoracic oncology database to capture radiological and pathological images for evaluation of response to chemotherapy in patients with malignant pleural mesothelioma. Issue 5 (26th October 2012)

9. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Issue 4 (April 2015)

10. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Issue 4 (April 2015)